NewBridge Pharmaceuticals is a specialty therapeutics and devices company positioned to become the leading provider of innovative healthcare products to the Middle East, North Africa and Turkey (MEA & Turkey). NBP will meet the unique needs of this expanding economic region with an experienced management team and a focused sales and marketing effort, bringing the appropriate branded FDA and EMEA-approved therapeutic products to the region through its licensing efforts with leading biotechnology and pharmaceutical companies. NBP will expand its business to include its own branded products through the establishment of manufacturing and R&D capabilities. This strategy will position NBP to become a paramount biotechnology company in the region.

Headquartered in Dubai, NBP was founded in 2007 by two preeminent investment firms, Burrill & Company (Burrill), a San Francisco-based Life Science Venture Capital and Merchant banking firm and National Technology Enterprises Company (NTEC), a Kuwait Investment Authority mandated fund operating out of Kuwait City. The Burrill/NTEC partnership allows NBP unprecedented access to US biotechnology companies, expertise and products as well as regional knowledge and investment expertise. NBP management includes a CEO with both regional and global experience in leading pharmaceutical commercialization teams having more than 25 successful product launches with combined total annual revenues over USD $400 million. NBP is establishing regulatory, supply chain and medical affairs competencies within the region and aims to significantly expand its capabilities over the next two years. These efforts will position NBP to be the “partner-of-choice” for US and European biotech and pharmaceutical companies seeking access to a rapidly expanding market. The initial product portfolio aims to addresses disease classes with sharply rising incidence and prevalence rates such as diabetes, cardiovascular disorders, metabolic disorders, and cancer.